FDA guidance
Characterizing, Collecting, and Reporting Immune-Mediated Adverse Reactions in Cancer…
FDA guidance · Draft · issued Oct 17, 2022
Key facts
| Title | Characterizing, Collecting, and Reporting Immune-Mediated Adverse Reactions in Cancer Immunotherapeutic Clinical Trials: Draft Guidance for Industry; Availability |
|---|---|
| Status | Draft |
| Issue date | Oct 17, 2022 |
| Center | Office of the Commissioner |
| Issuing office | Oncology Center of Excellence, Center for Biologics Evaluation and Research, Center for Drug Evaluation and Research |
| Communication type | Guidance Document |
| Regulated product | Biologics, Drugs |
| Docket number | FDA-2022-D-1744 |
| Open for comment | No |
| Document on fda.gov | fda.gov |
At a glance
- None Product codes referenced
- None Recognized standards referenced
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA guidance documents
FDA guidance documents describe the agency's current thinking on regulatory topics. Drafts are issued for comment before a final version is published.
Source: U.S. Food and Drug Administration (FDA), Guidance Documents